![\"Trump](\"https:\/\/news2.watchtowatch.top\/wp-content\/uploads\/2025\/11\/Screenshot_619-295x300-1.png\")
<\/p>\n<\/p>\n
\u2013 In a dramatic escalation of the fight over U.S. drug prices, President Donald Trump\u2019s administration has given the pharmaceutical industry a stark ultimatum: lower prescription costs for American patients within 60 days or face aggressive federal intervention.<\/p>\n
The White House announced this sweeping demand through\u00a017 letters<\/strong>\u00a0sent directly to the CEOs of the world\u2019s largest pharmaceutical companies. The message, read aloud by Press Secretary\u00a0Karoline Leavitt<\/p>\n <\/strong>\u00a0during a briefing, left little room for negotiation.<\/p>\n \u201cIf you refuse to step up, we\u2019ll deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,\u201d the letters warned.<\/p>\n The move marks one of the most ambitious attempts yet by any U.S. administration to take on pharmaceutical giants, signaling that the president intends to make prescription affordability a defining policy battle in his second term.<\/p>\n At the heart of the ultimatum is Trump\u2019s insistence on\u00a0\u201cMost-Favored-Nation\u201d (MFN) pricing.<\/strong> The principle is simple: Americans should not be paying more for the same drugs than patients in other wealthy countries.<\/p>\n Currently, U.S. patients often pay\u00a0two to three times<\/strong>\u00a0as much for life-saving medications compared to Europe or Canada. According to federal health data, the United States spends more per capita on prescription drugs than any other nation. Nearly\u00a0<\/p>\n Trump\u2019s MFN policy, outlined in an\u00a0executive order signed in May<\/strong>, demands that drugmakers extend their lowest global price to U.S. markets. The administration\u2019s letters expand this requirement to include:<\/p>\n Medicaid recipients<\/strong>\u00a0\u2013 ensuring the poorest Americans benefit directly.<\/p>\n Newly launched drugs<\/strong>\u00a0\u2013 requiring companies to set initial prices in line with their cheapest global rate.<\/p>\n Revenue repatriation<\/strong>\u00a0\u2013 calling on firms to return profits from inflated foreign prices to support American patients.<\/p>\n Direct purchasing options<\/strong>\u00a0\u2013 allowing patients to buy medications at MFN rates, bypassing middlemen like pharmacy benefit managers (PBMs).<\/p>\n \u201cGlobal freeloading ends with this administration,\u201d Trump wrote in his letter to Eli Lilly\u2019s CEO, David Ricks.<\/p>\n The pharmaceutical industry responded with a mix of alarm and guarded statements. Stocks in several major firms\u2014including Pfizer, Merck, and Johnson & Johnson\u2014dipped briefly following the announcement, though most rebounded within hours. Analysts suggested markets were betting on the industry\u2019s ability to resist or dilute the reforms.<\/p>\n Industry lobbyists argue that tying U.S. drug prices to international benchmarks could\u00a0cripple innovation<\/strong>, warning it would reduce funding for research and development of new treatments.<\/p>\n \u201cThe American system is what fuels medical breakthroughs,\u201d one pharmaceutical executive said anonymously. \u201cIf our pricing flexibility disappears, so does the next generation of cures.\u201d<\/p>\n Yet critics counter that this line has been used for decades to justify runaway profits. According to federal data, the pharmaceutical sector consistently ranks among the most profitable industries in the United States, often posting double-digit margins.<\/p>\n This is not Trump\u2019s first battle with the drug industry. During his first term, he launched initiatives aimed at price transparency and international reference pricing, but most were either watered down or struck down in court.<\/p>\n The difference this time is both\u00a0political capital and public pressure.<\/strong> Trump won reelection in 2024 promising to slash drug costs, and soaring prices have remained a top concern for voters across party lines. Polls show overwhelming bipartisan support for government action to curb costs.<\/p>\n The administration is also framing the issue as a matter of\u00a0economic fairness<\/strong>. Trump has repeatedly claimed that American patients are \u201csubsidizing\u201d low prices abroad, where governments negotiate aggressively with drugmakers while U.S. consumers are left to pay the balance.<\/p>\n \u201cOther nations negotiate, and they get a good deal. We don\u2019t negotiate\u2014we pay whatever Big Pharma asks,\u201d Trump said in a recent rally. \u201cThat ends now.\u201d<\/p>\n The\u00a060-day window<\/strong> is designed to force immediate responses while aligning with the fall legislative calendar. By setting a hard deadline, the White House increases pressure on both industry executives and members of Congress.<\/p>\n If drugmakers fail to present binding commitments, the administration has hinted at multiple options:<\/p>\n Regulatory changes through the\u00a0Department of Health and Human Services (HHS)<\/strong>.<\/p>\n Direct government negotiations on behalf of Medicare and Medicaid.<\/p>\n Expanded executive orders tying pricing to federal purchasing power.<\/p>\n Potential trade measures against companies deemed to be exploiting U.S. markets.<\/p>\n The ultimatum also sets up a potential legal showdown. Industry groups are already preparing lawsuits arguing that MFN pricing violates constitutional protections and international trade rules.<\/p>\n For Trump, the move is both politically risky and potentially rewarding. Successfully cutting drug prices would deliver a tangible benefit to millions of Americans, strengthening his populist brand.<\/p>\n But failure\u2014or even the perception of capitulation to Big Pharma\u2014could erode trust among his base.<\/p>\n Democrats, traditionally more supportive of drug pricing reforms, face a tricky political choice. Many support the idea of lowering costs but are reluctant to hand Trump a political victory. Some progressive lawmakers are already pushing for\u00a0<\/p>\n Meanwhile, Republican lawmakers are split. Fiscal conservatives worry about government overreach, while populist conservatives embrace the plan as a way to stand up to corporate power.<\/p>\n If the policy is enforced, the ripple effects could be felt worldwide. Drugmakers may respond by\u00a0raising prices abroad<\/strong>\u00a0to offset U.S. cuts, creating tension with European and Canadian governments.<\/p>\n Health economists also warn of a possible\u00a0two-tiered system<\/strong>: companies could prioritize releasing new drugs in countries willing to pay higher launch prices, delaying access for others.<\/p>\n However, supporters argue that forcing international parity would finally put American patients on equal footing, ending decades of lopsided pricing.<\/p>\n Drug pricing is only one piece of the U.S. healthcare cost puzzle, but it is among the most visible. Americans routinely encounter sticker shock at the pharmacy counter, making it a powerful political issue.<\/p>\n Experts say real reform will also require addressing structural inefficiencies, such as:<\/p>\n The role of\u00a0pharmacy benefit managers (PBMs)<\/strong>, who negotiate rebates behind closed doors.<\/p>\n Patent loopholes that extend monopolies on popular drugs.<\/p>\n Limited competition in the generic and biosimilar markets.<\/p>\n The Trump administration has signaled it may target PBMs next, accusing them of pocketing rebates that should lower costs for patients.<\/p>\n The next two months will be decisive. Pharmaceutical companies are expected to lobby aggressively, both behind the scenes in Washington and publicly through advertising campaigns warning of the risks of \u201cprice controls.\u201d<\/p>\n At the same time, consumer advocacy groups are preparing to rally in support of the ultimatum, highlighting personal stories of families crushed by medical bills.<\/p>\n Trump, known for his combative style, appears ready for a public showdown. \u201cWe\u2019re not asking,\u201d he said during a recent event. \u201cWe\u2019re telling them: lower your prices, or we\u2019ll do it for you.\u201d<\/p>\n The administration\u2019s 60-day ultimatum sets the stage for one of the most consequential battles between the U.S. government and the pharmaceutical industry in modern history.<\/p>\n For patients, the outcome could mean hundreds\u2014or even thousands\u2014of dollars in annual savings. For drugmakers, it represents an existential threat to their current business model.<\/p>\n The fight over drug prices has simmered for decades. Now, with a firm deadline and the weight of the presidency behind it, the battle is moving to the forefront of national politics.<\/p>\n Whether this ultimatum produces meaningful reform or dissolves into another round of stalemate will shape not only the cost of medicine in America but also the balance of power between government and industry for years to come.<\/p>\n Los Angeles, July 2025 \u2014 Vice President Kamala Harris is once again at the center of speculation over her political future, following striking comments made by her longtime political mentor \u2014 and former romantic partner \u2014 Willie Brown, the ex-mayor of San Francisco.<\/p>\n Brown, now 91, remains an influential voice in California Democratic politics despite having left public office more than two decades ago. In a recent interview with podcaster Jon Slavet, the former mayor offered a blunt assessment of Harris\u2019s career trajectory, suggesting that her next move might not include a run for governor \u2014 and perhaps should not.<\/p>\n Brown\u2019s Surprising Admission<\/p>\n In a clip from the interview that has circulated widely, Brown did not mince words about Harris\u2019s potential future in California politics.<\/p>\n \u201cShe may not want to run for governor of the state of California. That may not be where she should be going,\u201d Brown told Slavet. \u201cI think it\u2019s going to be difficult for her to win that job.\u201d<\/p>\n For Harris \u2014 who has served as a district attorney, attorney general of California, U.S. senator, and vice president \u2014 the comments land as both a personal and political jolt. Coming from someone who has been both a mentor and, decades ago, a romantic partner, Brown\u2019s remarks carry more weight than the average pundit\u2019s speculation.<\/p>\n A Mentor\u2019s Perspective<\/p>\n Slavet, recounting his discussion with Brown during an appearance on Los Angeles anchor Elex Michaelson\u2019s program, described the elder statesman as still sharp and candid at his advanced age.<\/p>\n \u201cFirst of all, kudos to Willie \u2014 age 91, still going strong, still sharp. I mean, I think that\u2019s amazing,\u201d Slavet said. \u201cHe, in effect, said he doesn\u2019t think governor is a fit for her.\u201d<\/p>\n According to Slavet, Brown praised Harris\u2019s background in the legal world but expressed doubts about her effectiveness as an executive leader.<\/p>\n \u201cHe talked about her strengths in the legal world, but not as an executive, which to me was pretty stunning because this is a guy who knows her very well,\u201d Slavet noted. \u201cHe\u2019s a legend in Democratic politics, right? He\u2019s been a mentor to Kamala. And he actually cares about the future of California authentically, and he in effect said she should try something different.\u201d<\/p>\n The Attorney General \u201cWhat-If\u201d<\/p>\n One of the more intriguing revelations from Brown was his claim that he had advised Harris against accepting the vice presidency when Joe Biden offered her the slot on his 2020 ticket.<\/p>\n According to Slavet, Brown chuckled as he recounted the moment. \u201cHe said, \u2018I got in trouble for this when I said it.\u2019 But what he told me is that when she was one of the final five and Biden was reviewing the final candidates, he recommended to her that she ask Biden to nominate her as attorney general instead.\u201d<\/p>\n The reasoning, Brown reportedly explained, was simple: Harris\u2019s skills as a prosecutor and legal strategist would shine in the role of the nation\u2019s top law enforcement officer, while the vice presidency \u2014 a position often defined by its lack of clear responsibilities \u2014 risked diluting her political brand.<\/p>\n \u201cShe\u2019s better in the legal world than as an executive,\u201d Brown believed, according to Slavet.<\/p>\n A Complicated Relationship<\/p>\n Brown\u2019s commentary is particularly striking given his personal history with Harris. The two were romantically linked in the mid-1990s, when Brown was speaker of the California State Assembly and Harris was beginning her legal career. While critics have long suggested that Harris benefited politically from the connection, she has consistently pushed back against attempts to reduce her career to that relationship.<\/p>\n Still, Brown has remained a fixture in discussions of Harris\u2019s political journey \u2014 sometimes as a defender, other times as a critic. His latest remarks fall somewhere in between, acknowledging her talents but questioning her long-term political strategy.<\/p>\n Harris\u2019s Political Dilemmas<\/p>\n Harris faces a unique set of challenges as she looks ahead. Her tenure as vice president has been marked by both historic firsts \u2014 as the first woman and the first person of both Black and South Asian descent to hold the office \u2014 and persistent criticisms.<\/p>\n Polling throughout Biden\u2019s presidency often showed Harris with approval ratings lower than the president\u2019s, a vulnerability that has dogged her since entering national office. Critics point to uneven messaging, high-profile missteps, and a perception that she has struggled to define her role within the administration.<\/p>\n Those weaknesses, Brown seemed to suggest, would make a run for California governor a risky move. Despite being Harris\u2019s home state, California\u2019s politics are notoriously complex, with fierce intra-party rivalries and an electorate that can be both deeply liberal and sharply pragmatic.<\/p>\n \u201cShe\u2019d be walking into a hornet\u2019s nest,\u201d one California political strategist, who requested anonymity, said when asked about Brown\u2019s comments. \u201cThere are already ambitious Democrats lining up for 2026 and beyond. Running for governor is not the safe bet some people think it is.\u201d<\/p>\n Looking Beyond Sacramento<\/p>\n If Brown is correct that Harris should not pursue the governorship, the question becomes: what next?<\/p>\n Some observers believe Harris could still seek a return to the Senate, though that would require waiting for an opening in one of California\u2019s seats. Others speculate she may angle for a Cabinet position in a future Democratic administration, particularly in the Justice Department, where her legal background would be most relevant.<\/p>\n There is also the possibility that Harris could position herself for another presidential run. While her 2020 campaign fizzled early, some allies believe her national profile as vice president gives her a stronger foundation should she try again in the future. Brown\u2019s comments, however, cast doubt on whether such a move would play to her strengths.<\/p>\n Brown\u2019s Legacy and Harris\u2019s Future<\/p>\n At 91, Willie Brown has nothing to lose by speaking bluntly. Known for decades as a kingmaker in California politics, his reputation for savvy maneuvering remains intact. Whether his latest advice proves prescient or not, it underscores the uncertainty surrounding Harris\u2019s political future.<\/p>\n For Harris, the stakes are high. After serving as vice president \u2014 one of the pinnacles of American politics \u2014 any step down could be seen as a setback. Yet Brown\u2019s words serve as a reminder that ambition must be balanced with strategy, and that even a resume as trailblazing as hers does not guarantee success in every arena.<\/p>\n Conclusion<\/p>\n Kamala Harris stands at a crossroads. Her vice presidency cemented her place in history, but the path forward is far less clear. Should she heed her mentor\u2019s advice and return to her legal roots? Or should she defy the doubts and pursue executive leadership in California or beyond?<\/p>\n What is certain is that her next move will be closely watched \u2014 not just by voters and pundits, but by her former mentor, who still seems invested in shaping the trajectory of a woman he once guided into the political spotlight.<\/p>\n As Brown himself put it: \u201cShe may not want to run for governor. That may not be where she should be going.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":" \u2013 In a dramatic escalation of the fight over U.S. drug prices, President Donald Trump\u2019s administration has given the pharmaceutical industry a stark ultimatum: lower prescription costs for American patients within 60…<\/p>\n","protected":false},"author":1,"featured_media":17813,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-17814","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-hot-news"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/news2.watchtowatch.top\/index.php?rest_route=\/wp\/v2\/posts\/17814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/news2.watchtowatch.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news2.watchtowatch.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news2.watchtowatch.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/news2.watchtowatch.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17814"}],"version-history":[{"count":0,"href":"https:\/\/news2.watchtowatch.top\/index.php?rest_route=\/wp\/v2\/posts\/17814\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news2.watchtowatch.top\/index.php?rest_route=\/wp\/v2\/media\/17813"}],"wp:attachment":[{"href":"https:\/\/news2.watchtowatch.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news2.watchtowatch.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news2.watchtowatch.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n<\/div>\n<\/div>\n